A Chicago-based arbitration panel ruled in favor of Eli Lilly and Company in a claim filed by Adocia S.A. over the companies’ prior collaboration on a rapid-acting insulin.
Leading scientists, public policy experts and biotech industry leaders joined forces to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance.
Shriners Hospitals for Children Announces New Medical Device for Scoliosis Treatment Approved by FDA
A new medical device for treating scoliosis – curvature of the spine – received FDA approval, providing an alternative that both corrects the curve and maintains flexibility in the spine.
Mallinckrodt Announces Positive Top-Line Results from Pivotal Phase 3 Study of Terlipressin in Patients with HRS-1
Mallinckrodt plc announced positive top-line results from the company’s pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1 (HRS-1).
Healthline Media appointed Steve Swasey as vice president of Communications and Laurie Dewan as vice president of Consumer Insights.
Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.
Oncologie Inc. announced a clinical collaboration agreement with Merck to evaluate the combination of Oncologie’s investigational drug Bavituximab – an antibody that blocks the activity of phosphatidylserine – and Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer.
McCann Health announced Hilary Gentile’s promotion to the newly created position of Global Chief Strategy Officer.
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form
Bausch Health Companies Inc. and the company’s dermatology business Ortho Dermatologics announced that the U.S. Food and Drug Administration accepted the New Drug Application for IDP-123 (tazarotene 0.045%) Lotion, with a PDUFA action date of Dec. 22, 2019.